We recently published 10 Big Names Beating Wall Street at Its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) was one of the top performers on Monday.
Recursion Pharmaceuticals soared 13.99% on Monday to close at $6.68 apiece as investors resorted to bargain hunting after a two-day decline while repositioning their portfolios ahead of the earnings release.
Based on its historical reporting dates, Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) will announce its third quarter financial and operating highlights results during the first week of November 2025.
To recall, Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported a 76% higher net loss in the second quarter of the year at $171.9 million compared to $97.5 million for the same period last year.
Revenue, on the other hand, increased 33% to $19.2 million, up from $14.4 million year-over-year, with the majority comprised primarily of revenue from collaboration agreements.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage biotechnology company that leverages sophisticated machine learning algorithms to distill a collection of billions of searchable relationships across biology and chemistry from its dataset. It’s one of the few companies in which tech giant Nvidia Corp. has a stake. directly invested.
While we recognize the potential of RXRX as an investment, our belief lies in the belief that certain AI stocks have more promise in terms of higher returns and have limited downside risk. If you’re looking for an extremely cheap AI stock that’s also a top beneficiary of Trump’s tariffs and relocation, check out our free report on the best AI stock in the short term.
READ NEXT: 30 stocks that should double in 3 years And 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published on Initiated Monkey.
